On Friday, October 20th, Kyle Giesler successfully defended his thesis, “The Design, Synthesis, and Evaluation of Novel LipidProdrugs for Nucleoside Analogues.” Kyle’s thesis committee included his thesis advisor, Dr. Dennis Liotta, and members Dr. Khalid Salaita and Dr. Frank McDonald.
During his time at Emory, Kyle designed a novel prodrug strategy for tenofovir and other antiviral nucleosides that “unlocks” their therapeutic potential and significantly rivals well-accepted conjugation strategies used in the clinic. His research contributed to 8 publications and a patent application. In addition, Kyle initiated a collaboration between Emory and Morehouse School of Medicine, developed analogs for the treatment of chronic viral infections and cancer, and was awarded the Graduate Diversity Fellowship awarded to outstanding graduate students showing academic excellence and “exceptional promise as future leaders in their fields”.
Looking forward, Kyle plans to pursue a post-doctoral position at U.C Berkeley with Dr. Nirem Murthy where he intends to jump into bioengineering and develop delivery strategies for genome editing technology. After that, Kyle hopes to land an industrial position at the interface of chemistry and biology and be a part of a creative and team that operates at the forefront of human knowledge to design and discover novel therapeutics to change the course of human disease.
Congratulations, Dr. Giesler!